SCHEMBL1455969

SCHEMBL1455969

Nc1nc(CCN2CCOCC2)cc(-c2c[nH]c3ncccc23)n1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDPK1 O15530 9/20 0.66
▸ CCNB2 O95067 2/20 0.56
▸ CDK1 P06493 2/20 0.56
▸ CCNB1 P14635 2/20 0.56
▸ CCNB3 Q8WWL7 2/20 0.56
▸ CDK9 P50750 4/20 0.55
▸ CDC7 O00311 4/20 0.55
▸ CDK5 Q00535 3/20 0.55
▸ DAPK3 O43293 2/20 0.55
▸ PRKD3 O94806 2/20 0.55
▸ MAP4K4 O95819 2/20 0.55
▸ PAK4 O96013 2/20 0.55
▸ PIM1 P11309 2/20 0.55
▸ PRKACA P17612 2/20 0.55
▸ CSNK1A1 P48729 2/20 0.55
▸ CLK2 P49760 2/20 0.55
▸ GSK3A P49840 2/20 0.55
▸ GSK3B P49841 2/20 0.55
▸ CDK7 P50613 2/20 0.55
▸ PRKX P51817 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1604181 0.94 PDPK1 (0.68) PDPK1CCNB2CDK1CCNB1CCNB3
SCHEMBL1456041 0.89 PDPK1 (0.70) PDPK1CCNB2CDK1CCNB1CCNB3
SCHEMBL1603904 0.85 PDPK1 (0.72) PDPK1CCNB2CDK1CCNB1CCNB3
SCHEMBL1456489 0.84 PDPK1 (0.62) PDPK1CCNB2CDK1CCNB1CCNB3
SCHEMBL12707224 0.83 PDPK1 (0.71) PDPK1CDK1CCNB1CDK9CDC7
SCHEMBL1605027 0.83 PDPK1 (0.69) PDPK1CCNB2CDK1CCNB1CCNB3
SCHEMBL1604217 0.80 PDPK1 (1.00) PDPK1CDK9CDC7CDK5DAPK3
SCHEMBL1603905 0.79 PDPK1 (0.80) PDPK1CDK9CDC7CDK5DAPK3
SCHEMBL1603808 0.79 PDPK1 (1.00) PDPK1CDK9CDC7CDK5DAPK3
SCHEMBL1603523 0.78 PDPK1 (1.00) PDPK1CDK9CDC7CDK5DAPK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8420820-B2 Pyrrolopyridinylpyrimidin-2-ylamine derivatives MERCK PATENT GMBH (DE) 2013-04-16 — — US claimed
JP-2011526260-A — — 2011-10-06 — — JP claimed
US-20110218198-A1 Pyrrolopyridinylpyrimidin-2-ylamine derivatives MERCK PATENT GESELLSCHAFT (DE) 2011-09-08 — — US claimed
EP-2291375-A1 PYRROLOPYRIDINYLPYRIMIDIN-2-YLAMINE DERIVATIVES Merck Patent GmbH (DE) 2011-03-09 — — EP claimed
WO-2010000364-A1 PYRROLOPYRIDINYLPYRIMIDIN-2-YLAMINE DERIVATIVES MERCK PATENT GMBH (DE) 2010-01-07 — — WO claimed
US-8420820-B2 Pyrrolopyridinylpyrimidin-2-ylamine derivatives MERCK PATENT GMBH (DE) 2013-04-16 — — US disclosed
US-8420820-B2 Pyrrolopyridinylpyrimidin-2-ylamine derivatives MERCK PATENT GMBH (DE) 2013-04-16 — — US disclosed
US-20110218198-A1 Pyrrolopyridinylpyrimidin-2-ylamine derivatives MERCK PATENT GESELLSCHAFT (DE) 2011-09-08 — — US disclosed
US-20110218198-A1 Pyrrolopyridinylpyrimidin-2-ylamine derivatives MERCK PATENT GESELLSCHAFT (DE) 2011-09-08 — — US disclosed
EP-2291375-A1 PYRROLOPYRIDINYLPYRIMIDIN-2-YLAMINE DERIVATIVES Merck Patent GmbH (DE) 2011-03-09 — — EP disclosed
WO-2010000364-A1 PYRROLOPYRIDINYLPYRIMIDIN-2-YLAMINE DERIVATIVES MERCK PATENT GMBH (DE) 2010-01-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110218198-A1 Pyrrolopyridinylpyrimidin-2-ylamine derivatives MKI67, CCNT1, CCNI PDPK1 429/4885CCNB2 32/4885CDK1 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback